Lords Mark opens IVD plant two months early, expands capacity by 70%
The ₹67-cr nano-cap is moving beyond NBFC into diagnostics with a new Vasai facility and plans for cancer detection and AI-enabled devices.
— 2 earlier stories on Lords Mark Industries Ltd. →What's new
- Commissioned 14,000 sq. ft. IVD unit at Vasai, two months ahead of schedule.
- Total operational space expands from 20,000 to 34,000 sq. ft.
- Plans for cancer detection facility (2029) and AI-enabled medical device plant.
Why this matters
For a company with a ₹67-cr market cap but ₹491-cr quarterly sales, the capacity expansion signals a strategic pivot from NBFC to high-margin diagnostics. The early launch and product portfolio (56 ELISA kits) strengthen the growth narrative, though no revenue impact is quantified yet.
What we're watching
- Revenue contribution from IVD sales in coming quarters.
- Progress on the cancer detection facility and AI-enabled plant.
- Whether diagnostics EBITDA margins exceed those of the NBFC business.
The full read
Lords Mark Industries, a nano-cap with a ₹67-crore market cap but surprising scale (₹491 crore quarterly sales), has commissioned a 14,000 sq. ft. IVD manufacturing unit at Vasai two months ahead of schedule. The facility boosts total operational space by 70% to 34,000 sq. ft. and will produce 56 ELISA test kits and rapid diagnostics. The R&D wing is dedicated to the late Ratan Tata. Further plans include a cancer detection facility (named after Dr. A.P.J. Abdul Kalam) by January 2029 and a long-term vision for an AI-enabled medical device plant. For a company that generated ₹684.7 crore in FY26 revenue, this expansion is a material step into high-margin diagnostics. The pace at which this new business shifts the revenue mix will determine the real impact.
Questions answered
- How much did the new facility cost?
- The filing does not disclose the capital expenditure for the Vasai plant.
- What is Lords Mark's current revenue mix?
- The company operates as an NBFC, with latest quarterly sales of ₹491 crore. The diagnostics segment is new and expected to contribute going forward.
- When will production begin?
- The facility has been commissioned, so production of ELISA and rapid diagnostics kits should start immediately.
- Is this a pivot from NBFC to diagnostics?
- Yes, the capacity expansion and planned facilities for cancer detection and AI-enabled devices indicate a strategic shift into high-margin med-tech.
Lords Mark Industries Ltd.
Latest quarter · Mar 2026
Leverage & growth
Story so far
All notes on KRATOSENER →- 23 Jun 2026 · 4:21 PM IST Lords Mark opens IVD plant two months early, expands capacity by 70%
- 15d ago Lords Mark clears legal hurdle to listing with ₹16.25 cr warrant conversion
- 24d ago Lords Mark's first full-year result shows ₹684.7 cr revenue on ₹67 cr market cap